ES2629211T3 - (1R,4R)-6'-fluor-(N-metil- o N,N-dimetil-)-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina para el tratamiento de la fibromialgia y el síndrome de fatiga crónica - Google Patents
(1R,4R)-6'-fluor-(N-metil- o N,N-dimetil-)-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina para el tratamiento de la fibromialgia y el síndrome de fatiga crónica Download PDFInfo
- Publication number
- ES2629211T3 ES2629211T3 ES13701807.3T ES13701807T ES2629211T3 ES 2629211 T3 ES2629211 T3 ES 2629211T3 ES 13701807 T ES13701807 T ES 13701807T ES 2629211 T3 ES2629211 T3 ES 2629211T3
- Authority
- ES
- Spain
- Prior art keywords
- weight
- indole
- dihydro
- phenyl
- amine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000001640 Fibromyalgia Diseases 0.000 title abstract description 13
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 title abstract description 3
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 title abstract description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title description 24
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 title description 12
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 title description 12
- 150000001875 compounds Chemical class 0.000 abstract description 15
- 239000002552 dosage form Substances 0.000 abstract description 15
- 150000003839 salts Chemical class 0.000 abstract description 4
- -1 polyoxyethylene Polymers 0.000 description 14
- 210000000627 locus coeruleus Anatomy 0.000 description 13
- 239000004094 surface-active agent Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 210000002569 neuron Anatomy 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- 229930195729 fatty acid Natural products 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 230000008925 spontaneous activity Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000010304 firing Methods 0.000 description 3
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000006104 solid solution Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Chemical compound CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002159 nanocrystal Substances 0.000 description 2
- 230000002474 noradrenergic effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- GNWCZBXSKIIURR-UHFFFAOYSA-N (2-docosanoyloxy-3-hydroxypropyl) docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCCCCCC GNWCZBXSKIIURR-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- QIZPVNNYFKFJAD-UHFFFAOYSA-N 1-chloro-2-prop-1-ynylbenzene Chemical compound CC#CC1=CC=CC=C1Cl QIZPVNNYFKFJAD-UHFFFAOYSA-N 0.000 description 1
- WECGLUPZRHILCT-GSNKCQISSA-N 1-linoleoyl-sn-glycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)CO WECGLUPZRHILCT-GSNKCQISSA-N 0.000 description 1
- 229940114072 12-hydroxystearic acid Drugs 0.000 description 1
- FZZMTSNZRBFGGU-UHFFFAOYSA-N 2-chloro-7-fluoroquinazolin-4-amine Chemical compound FC1=CC=C2C(N)=NC(Cl)=NC2=C1 FZZMTSNZRBFGGU-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- XZAGBDSOKNXTDT-UHFFFAOYSA-N Sucrose monopalmitate Chemical compound CCCCCCCCCCCCCCCC(O)=O.OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(CO)O1 XZAGBDSOKNXTDT-UHFFFAOYSA-N 0.000 description 1
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 1
- KGUHOFWIXKIURA-VQXBOQCVSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl dodecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCC)O[C@@H]1O[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](CO)O1 KGUHOFWIXKIURA-VQXBOQCVSA-N 0.000 description 1
- FOLJTMYCYXSPFQ-CJKAUBRRSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-(octadecanoyloxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl octadecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)O[C@@H]1O[C@@]1(COC(=O)CCCCCCCCCCCCCCCCC)[C@@H](O)[C@H](O)[C@@H](CO)O1 FOLJTMYCYXSPFQ-CJKAUBRRSA-N 0.000 description 1
- OCRUMFQGIMSFJR-FSAWCSQFSA-N [(2s,3s,4r,5r)-4-hydroxy-5-(hydroxymethyl)-3-[(z)-octadec-9-enoyl]oxy-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl (z)-octadec-9-enoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCC\C=C/CCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC OCRUMFQGIMSFJR-FSAWCSQFSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000037328 acute stress Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- UHUSDOQQWJGJQS-UHFFFAOYSA-N glycerol 1,2-dioctadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCC UHUSDOQQWJGJQS-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940072106 hydroxystearate Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940032085 sucrose monolaurate Drugs 0.000 description 1
- 229940035023 sucrose monostearate Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12000743 | 2012-02-03 | ||
| EP12000743 | 2012-02-03 | ||
| PCT/EP2013/051979 WO2013113857A1 (en) | 2012-02-03 | 2013-02-01 | (1r,4r)-6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro-[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for treating fibromyalgia and chronic fatigue syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2629211T3 true ES2629211T3 (es) | 2017-08-07 |
Family
ID=47628188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13701807.3T Active ES2629211T3 (es) | 2012-02-03 | 2013-02-01 | (1R,4R)-6'-fluor-(N-metil- o N,N-dimetil-)-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina para el tratamiento de la fibromialgia y el síndrome de fatiga crónica |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20130202701A1 (enExample) |
| EP (1) | EP2809320B1 (enExample) |
| JP (1) | JP6126134B2 (enExample) |
| KR (1) | KR102061482B1 (enExample) |
| CN (1) | CN104168897B (enExample) |
| AU (1) | AU2013214223B2 (enExample) |
| BR (1) | BR112014019136A8 (enExample) |
| CA (1) | CA2863572C (enExample) |
| CY (1) | CY1118799T1 (enExample) |
| DK (1) | DK2809320T3 (enExample) |
| EA (1) | EA025500B1 (enExample) |
| ES (1) | ES2629211T3 (enExample) |
| HR (1) | HRP20170581T1 (enExample) |
| IL (1) | IL233871B (enExample) |
| LT (1) | LT2809320T (enExample) |
| MX (1) | MX353740B (enExample) |
| NZ (1) | NZ629800A (enExample) |
| PL (1) | PL2809320T3 (enExample) |
| PT (1) | PT2809320T (enExample) |
| RS (1) | RS56097B1 (enExample) |
| SI (1) | SI2809320T1 (enExample) |
| WO (1) | WO2013113857A1 (enExample) |
| ZA (1) | ZA201406447B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10022353B2 (en) | 2015-01-23 | 2018-07-17 | Grünenthal GmbH | Cebranopadol for treating pain in subjects with impaired hepatic and/or impaired renal function |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5900420A (en) * | 1997-06-19 | 1999-05-04 | Cole; William L. | Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine |
| DE10252667A1 (de) * | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| DE10360792A1 (de) * | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| BRPI0509377A (pt) * | 2004-03-29 | 2007-09-11 | Pfizer | compostos de ácido alfa arila ou heteroaril metil beta piperidino propanóico como antagonistas do receptor orl1 |
| MX2008015048A (es) * | 2006-05-31 | 2008-12-10 | Sepracor Inc | Tratamiento contra trastornos de dolor con trans 4-(3,4-diclorofenil)-1,2,3,4-tetrahidro-1-naftalenamina y su formamida. |
| DE102006046745A1 (de) * | 2006-09-29 | 2008-04-03 | Grünenthal GmbH | Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz |
-
2013
- 2013-02-01 LT LTEP13701807.3T patent/LT2809320T/lt unknown
- 2013-02-01 US US13/757,223 patent/US20130202701A1/en not_active Abandoned
- 2013-02-01 SI SI201330672A patent/SI2809320T1/sl unknown
- 2013-02-01 MX MX2014008865A patent/MX353740B/es active IP Right Grant
- 2013-02-01 HR HRP20170581TT patent/HRP20170581T1/hr unknown
- 2013-02-01 DK DK13701807.3T patent/DK2809320T3/en active
- 2013-02-01 JP JP2014555212A patent/JP6126134B2/ja active Active
- 2013-02-01 RS RS20170602A patent/RS56097B1/sr unknown
- 2013-02-01 NZ NZ629800A patent/NZ629800A/en not_active IP Right Cessation
- 2013-02-01 CA CA2863572A patent/CA2863572C/en not_active Expired - Fee Related
- 2013-02-01 AU AU2013214223A patent/AU2013214223B2/en not_active Ceased
- 2013-02-01 ES ES13701807.3T patent/ES2629211T3/es active Active
- 2013-02-01 EA EA201400857A patent/EA025500B1/ru not_active IP Right Cessation
- 2013-02-01 BR BR112014019136A patent/BR112014019136A8/pt not_active Application Discontinuation
- 2013-02-01 PL PL13701807T patent/PL2809320T3/pl unknown
- 2013-02-01 KR KR1020147024696A patent/KR102061482B1/ko not_active Expired - Fee Related
- 2013-02-01 EP EP13701807.3A patent/EP2809320B1/en active Active
- 2013-02-01 CN CN201380007809.0A patent/CN104168897B/zh not_active Expired - Fee Related
- 2013-02-01 PT PT137018073T patent/PT2809320T/pt unknown
- 2013-02-01 WO PCT/EP2013/051979 patent/WO2013113857A1/en not_active Ceased
-
2014
- 2014-07-30 IL IL233871A patent/IL233871B/en active IP Right Grant
- 2014-09-02 ZA ZA2014/06447A patent/ZA201406447B/en unknown
-
2017
- 2017-04-03 CY CY20171100395T patent/CY1118799T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1199218A1 (en) | 2015-06-26 |
| AU2013214223B2 (en) | 2017-03-23 |
| US20130202701A1 (en) | 2013-08-08 |
| CN104168897A (zh) | 2014-11-26 |
| CA2863572C (en) | 2019-08-27 |
| EA201400857A1 (ru) | 2015-01-30 |
| EA025500B1 (ru) | 2016-12-30 |
| JP6126134B2 (ja) | 2017-05-10 |
| CA2863572A1 (en) | 2013-08-08 |
| KR102061482B1 (ko) | 2020-01-03 |
| KR20140130695A (ko) | 2014-11-11 |
| NZ629800A (en) | 2016-06-24 |
| ZA201406447B (en) | 2016-02-24 |
| EP2809320A1 (en) | 2014-12-10 |
| IL233871B (en) | 2018-06-28 |
| PT2809320T (pt) | 2017-06-30 |
| SI2809320T1 (sl) | 2017-07-31 |
| WO2013113857A1 (en) | 2013-08-08 |
| BR112014019136A2 (enExample) | 2017-06-20 |
| IL233871A0 (en) | 2014-09-30 |
| MX353740B (es) | 2018-01-26 |
| PL2809320T3 (pl) | 2017-09-29 |
| DK2809320T3 (en) | 2017-05-15 |
| RS56097B1 (sr) | 2017-10-31 |
| MX2014008865A (es) | 2014-08-27 |
| BR112014019136A8 (pt) | 2017-07-11 |
| EP2809320B1 (en) | 2017-03-22 |
| CY1118799T1 (el) | 2018-01-10 |
| CN104168897B (zh) | 2016-09-28 |
| AU2013214223A1 (en) | 2014-09-18 |
| HRP20170581T1 (hr) | 2017-06-16 |
| JP2015505553A (ja) | 2015-02-23 |
| LT2809320T (lt) | 2017-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2600851T3 (en) | PHARMACEUTICAL DOSAGE FORM CONTAINING 6'-FLUORO- (N-METHYL OR N, N-DIMETHYL -) - 4-PHENYL-4 ', 9'-DIHYDRO-3'H-SPIRO [CYCLOHEXAN-1,1'-PYRANO [3,4, B] INDOL] -4-AMINE FOR TREATMENT OF NEUROPATHIC PAIN | |
| EP3578172B1 (en) | Solid solution compositions and use in chronic inflammation | |
| AU2013294915C1 (en) | Opioid formulations | |
| DK2600838T3 (en) | PHARMACEUTICAL DOSAGE FORM CONTAINING 6'-FLUORO- (N-METHYL- OR N, N-DIMETHYL-) - 4-PHENYL-4 ', 9'-DIHYDRO-3'H-SPIRO [CYCLOHEXAN-1,1'-PYRANO [3 , 4, b] indole] -4-amine. | |
| ES2563735T3 (es) | Forma de dosificación farmacéutica que comprende 6'-fluor-(N-metil- o N,N-dimetil-)-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina | |
| US20250049783A1 (en) | Opioid formulations | |
| ES2983643T3 (es) | Terapia oral con tridecanoato de testosterona | |
| RU2017111503A (ru) | КОМПОЗИЦИИ(17-β)-3-ОКСОАНДРОСТ-4-ЕН-17-ИЛ УНДЕКАНОАТА И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ | |
| JP2017530149A (ja) | 低用量経口イソトレチノイン医薬組成物 | |
| ES2629211T3 (es) | (1R,4R)-6'-fluor-(N-metil- o N,N-dimetil-)-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina para el tratamiento de la fibromialgia y el síndrome de fatiga crónica | |
| AU2010240654B2 (en) | Sublingual spray formulation comprising dihydroartemesinin | |
| BR112020010519A2 (pt) | formulação farmacêutica de oxima de 3¿lfa-etinil-3¿eta-hidroxiandrostan-17-ona | |
| JP2016514706A5 (enExample) | ||
| WO2023100138A1 (en) | Oral cannabinoid compositions and methods for treating neurological diseases and disorders | |
| JP5852816B2 (ja) | 液状医薬組成物、及びこれを含有する軟カプセル剤 | |
| CN103565787B (zh) | 一种含蓬莪术环二烯的药物组合物及其制药用途 | |
| RU2795027C2 (ru) | Фармацевтический препарат | |
| CN110115766B (zh) | 一种含有氟比洛芬酯的复方制剂及其制备方法 | |
| HK40018887B (en) | Solid solution compositions and use in chronic inflammation | |
| HK40018887A (en) | Solid solution compositions and use in chronic inflammation | |
| HK1216004B (en) | Solid solution compositions and use in chronic inflammation | |
| GB2469791A (en) | Lipophilic compositions comprising an artemisinin derivative and their therapeutic uses |